We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Elevated plasma level of the glycolysis byproduct methylglyoxal on admission is an independent biomarker of mortality in ICU COVID-19 patients.
- Authors
Alomar, Fadhel A.; Alshakhs, Marai N.; Abohelaika, Salah; Almarzouk, Hassan M.; Almualim, Mohammed; Al-Ali, Amein K.; Al-Muhanna, Fahad; Alomar, Mohammed F.; Alhaddad, Mousa J.; Almulaify, Mohammed S.; Alessa, Faisal S.; Alsalman, Ahmed S.; Alaswad, Ahmed; Bidasee, Sean R.; Alsaad, Hassan A.; Alali, Rudaynah A.; AlSheikh, Mona H.; Akhtar, Mohammed S.; Al Mohaini, Mohammed; Alsalman, Abdulkhaliq J.
- Abstract
Biomarkers to identify ICU COVID-19 patients at high risk for mortality are urgently needed for therapeutic care and management. Here we found plasma levels of the glycolysis byproduct methylglyoxal (MG) were 4.4-fold higher in ICU patients upon admission that later died (n = 33), and 1.7-fold higher in ICU patients that survived (n = 32),compared to uninfected controls (n = 30). The increased MG in patients that died correlated inversely with the levels of the MG-degrading enzyme glyoxalase-1 (r2 = − 0.50), and its co-factor glutathione (r2 = − 0.63), and positively with monocytes (r2 = 0.29). The inflammation markers, SSAO (r2 = 0.52), TNF-α (r2 = 0.41), IL-1β (r2 = 0.25), CRP (r2 = 0.26) also correlated positively with MG. Logistic regression analysis provides evidence of a significant relationship between the elevated MG upon admission into ICU and death (P < 0.0001), with 42% of the death variability explained. From these data we conclude that elevated plasma MG on admission is a novel independent biomarker that predicts mortality in ICU COVID-19 patients.
- Subjects
COVID-19; PYRUVALDEHYDE; LOGISTIC regression analysis; BIOMARKERS; HOSPITAL admission &; discharge
- Publication
Scientific Reports, 2022, Vol 12, Issue 1, p1
- ISSN
2045-2322
- Publication type
Article
- DOI
10.1038/s41598-022-12751-y